And Eli Lilly has work to do ...The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker.
[not enough people took it to 12 months of use]
This too is an IV drug - likely as expensive as the last one I mentioned.
“modestly less cognitive and functional decline” in patients with early Alzheimer’s
[what happens later on - longer use profile ?]
the drug was associated with some adverse events, such as cerebral swelling or effusions
[fingers crossed that isn't a problem]
-----------------------
Still .. if It's an expensive IV drug ... it's really not going to compete with EXELON (IMO).